OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 3.03 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 782.68K shares, a 3770.04% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 57.83K shares, a 89.51% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-09-30 was 20.22K shares, a 97.07% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-06-30 was 66.18K shares, a 88.33% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 735.19K shares, a 69.84% decline from fiscal 2023.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 2.44M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.03M shares 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | 782.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.17M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 391.49K shares 10-Q · filed 2025-08-04 | |||
| 2024-12-31 | 57.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | 78.06K shares derived: sum of 2 quarters · filed 2025-03-05 | 144.24K shares derived: sum of 3 quarters · filed 2025-03-05 | 735.19K shares 10-K · filed 2025-03-05 |
| 2024-09-30 | 20.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 86.41K shares derived: sum of 2 quarters · filed 2024-11-14 | 677.35K shares 10-Q · filed 2024-11-14 | 1.23M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 66.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 657.13K shares 10-Q · filed 2024-08-08 | 1.21M shares derived: sum of 3 quarters · filed 2024-08-08 | 1.90M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 590.95K shares 10-Q · filed 2024-05-14 | 1.14M shares derived: sum of 2 quarters · filed 2024-05-14 | 1.83M shares derived: sum of 3 quarters · filed 2024-05-14 | 2.40M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 551.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | 1.24M shares derived: sum of 2 quarters · filed 2024-04-16 | 1.81M shares derived: sum of 3 quarters · filed 2024-04-16 | 2.44M shares 10-K · filed 2024-04-16 |
| 2023-09-30 | 690.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.26M shares derived: sum of 2 quarters · filed 2023-11-09 | 1.89M shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 567.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 1.20M shares 10-Q · filed 2023-08-21 | ||
| 2023-03-31 | 628.12K shares 10-Q · filed 2023-05-05 | |||
| 2022-09-30 | 497.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 2.74M shares derived: sum of 2 quarters · filed 2022-11-08 | 2.87M shares 10-Q · filed 2022-11-08 | |
| 2022-06-30 | 2.24M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | 2.38M shares 10-Q · filed 2022-08-05 | ||
| 2022-03-31 | 130.33K shares 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 274.22K shares 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | 274.22K shares 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |